Business
Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans
RAHWAY, N.J., December 19, 2025--Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans
About this update from Merck & Company, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":217,"url":"https://media.zenfs.com/en/business-wire.com/0cf4e6d27855490aa97643bdad47d2a8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AVHDKOq.TO3gJ3C_2vMwFQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQzNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/0cf4e6d27855490aa97643bdad47d2a8","width":480,"height":217}},"lazy":false},{"type":"text","content":"Enlicitide has potential to be first approved oral PCSK9 inhibitor designed to help meet critical unmet needs for patients and will be offered at an affordable price to eligible Americans through a direct-to-patient program","length":223,"tagName":"p","attribs":{}},{"type":"text","content":"Merck has committed more than $70 billion in U.S. investments to boost domestic production and innovation","length":105,"tagName":"p","attribs":{}},{"type":"text","content":"RAHWAY, N.J., December 19, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced a historic agreement with the Trump administration to ensure its prescription medicines are both accessible and affordable for Americans. This agreement enables Merck to continue its long-standing commitment to develop and deliver life-changing medicines and vaccines, and ensure Americans have access to those innovations at lower costs.","length":477,"tagName":"p"},{"type":"text","content":""As an American company, Merck is proud to work with the Trump administration to further secure our country’s position as a world leader in biopharmaceutical innovation. Today’s agreement marks a pivotal step in ensuring Americans can access medicines they need at lower costs," said Robert M. Davis, chairman and chief executive officer, Merck. "For too long, global pricing imbalances have shifted the financial burden of groundbreaking research and development onto the U.S. health care system and ultimately, American patients. Merck remains committed to expanding access and improving affordability across the system."","length":643,"tagName":"p"},{"type":"text","content":"Merck is working with the administration to reduce disparities in drug prices between the U.S. and other nations so American patients no longer shoulder a disproporti...